Enclomiphene
Enclomiphene citrate
Enclomiphene (Enclomiphene citrate) is a hormonal & sexual research compound. Estrogen-receptor antagonist at the hypothalamus — removes estrogen's brake so LH/FSH rise and testicular testosterone increases.
Enclomiphene quick facts
| Reported research dose | 12.5mg-25mg |
| Route | Oral |
| Frequency | 1x Daily |
| Half-life | ~10 hrs |
| Forms | Oral |
| Evidence level | Human trials |
Raise your own testosterone while keeping fertility — the isomer that does the job without clomid's baggage.
How Enclomiphene works
Estrogen-receptor antagonist at the hypothalamus — removes estrogen's brake so LH/FSH rise and testicular testosterone increases.
Proposed benefits
Natural testosterone support by raising LH/FSH without crashing estrogen.
Where to get Enclomiphene
Buy Enclomiphene at AlgoRx →The evidence for Enclomiphene
Graded by what exists behind each claim.
✅ Clinically validated
- Phase 3 trials were completed by Repros Therapeutics in men with secondary hypogonadism, showing raised total testosterone while preserving sperm concentration — which testosterone replacement does not.
- The FDA declined approval, on trial-design and endpoint grounds rather than a safety finding. That distinction is routinely lost: this is a compound with positive phase 3 data that did not clear a regulatory bar, not one that failed to work.
📊 Correlative data
- Heavy real-world use through telehealth as a testosterone-sparing alternative to TRT. The consistent clinical report matches the trials — testosterone rises, fertility is maintained, and a minority get mood or visual side effects.
🧪 Theoretical / extrapolated
- The trans-isomer of clomiphene, isolated. Clomiphene is a mixture of enclomiphene (an estrogen receptor antagonist at the pituitary, which raises LH) and zuclomiphene (a long-lived partial agonist with a half-life of weeks).
- Separating them is the entire point: zuclomiphene accumulates and is blamed for the mood and visual effects of clomiphene, so the isolated isomer is predicted to deliver the LH rise with less of the baggage.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Enclomiphene actually does
Enclomiphene is a subtraction, and the whole page is about what was subtracted. Clomiphene citrate is an approved drug that contains two geometric isomers. Enclomiphene is the trans isomer on its own, with the cis isomer — zuclomiphene — taken out. Nothing was added, nothing was redesigned, and the molecule that remains was already circulating in anyone who ever took clomiphene. What changed is what is no longer in the capsule.
What the trans isomer does on its own. It occupies the estrogen receptor in the hypothalamus without transducing the signal. In a male the dominant negative feedback on GnRH pulse generation is estradiol, so blocking that receptor lifts the brake: GnRH pulses more often, the pituitary releases more LH and more FSH, and both arms of the testis respond — Leydig cells make testosterone, Sertoli cells keep spermatogenesis supplied. The FSH arm is the part exogenous testosterone can never reproduce, and it is the reason this drug and a testosterone gel are not interchangeable even when they produce the same serum number.
What the separation was supposed to buy, stated as an experiment rather than as marketing. Fontenot 2016 took the two isomers apart and gave them to male mice by oral gavage, chronically, at 4 and 40 mg/kg/day each against placebo. The zuclomiphene arms showed profound effects on Leydig cells, epididymis, seminal vesicles and kidneys, together with disturbance of serum testosterone, FSH and LH. The isolated enclomiphene arm produced positive effects on testosterone production and no effects on testicular histology. The authors' own conclusion is that this “justifies the case for a monoisomeric preparation”. So the argument for enclomiphene is not that it is a better estrogen antagonist — it is that the other isomer, in a rodent, was actively harmful to the exact tissues the drug is taken to protect.
The second half of the argument is kinetic and it is why the separation matters more with time. Zuclomiphene is the slow isomer; the clomiphene label records detectable zuclomiphene more than a month after dosing U.S. Food and Drug Administration 2012. Remove it and there is nothing to accumulate. A monoisomeric antagonist therefore has a property clomiphene structurally cannot have: the composition of what is in your blood at week eight is the same as what was in it at day two.
One consequence nobody flags: this drug overshoots the gonadotropins. In its own phase II, enclomiphene “consistently increased serum total testosterone into the normal range and increased LH and FSH above the normal range” Wiehle 2013. That is not a side effect of a poorly chosen dose — it is what removing a feedback brake does. It also means an LH or FSH result on this drug cannot be read against a normal reference range in the usual way; supraphysiological gonadotropins are the expected finding, not evidence of a pituitary problem.
Cell, rodent, human — and where it stops
Step one, the animal work is the isomer comparison Fontenot 2016, described above: mice, oral gavage, 4 and 40 mg/kg/day, injury confined to the zuclomiphene arms. There is no rodent efficacy program for enclomiphene in the ordinary sense, because the compound entered human trials as half of a drug that had been on the market since the 1960s.
Step two, the 24-hour pharmacodynamic study, and it is the best single piece of evidence this compound has. Wiehle 2013 was a randomized, single-blind, two-center phase II study of three doses of enclomiphene citrate — 6.25 mg, 12.5 mg and 25 mg — against 5 g of transdermal testosterone gel in men with secondary hypogonadism. 48 men enrolled, 44 completed per protocol. Total testosterone and LH were sampled every hour for 24 hours, on day 1 and again after six weeks of daily dosing. At day 42 the mean trough total testosterone was 604 ± 160 ng/dL on 25 mg enclomiphene against 500 ± 278 ng/dL on the gel — not different from each other (p = 0.23), and note which arm carries the smaller standard deviation. All three enclomiphene doses raised trough, average, maximum and minimum testosterone across the day. The gel raised testosterone too, “albeit with more variability, and with suppressed LH levels”.
Step three, the fertility endpoint, which is the whole reason this class exists. Kaminetsky 2013 was a proof-of-principle randomized, open-label, active-control, two-center phase IIb study in 12 men with secondary hypogonadism who had previously been on topical testosterone. After washout, morning testosterone averaged 165 ± 66; at six months it was 545 ± 268 on gel and 525 ± 256 on enclomiphene. The separation is in the semen: enclomiphene raised sperm counts in 7 of 7 men at 3 months and 6 of 6 at 6 months, with concentrations in the 75–334 × 106/mL range, while the gel failed to raise counts above 20 × 106/mL in all five men at 3 months and moved only two of five by 6 months. Same testosterone, opposite fertility outcome.
Step four, the registered trial. Wiehle 2014 is the randomized phase II comparing enclomiphene with 1% topical testosterone gel, registered as NCT01270841. Its primary measures were LH, FSH, testosterone and semen analysis; the reported result is that enclomiphene produced morning testosterone, estradiol and LH increases similar to the gel, raised FSH and LH, and conserved sperm counts. Its conclusion is the cleanest sentence in this literature: enclomiphene “reverses the two hallmarks of secondary hypogonadism, namely, low serum total T and low or inappropriately normal LH while preserving sperm production”.
Step five, where the chain stops, and it stops at a regulator rather than at a result. There is no FDA-approved enclomiphene product. The molecule reached phase II under a trial name and did not become a licensed medicine; clomiphene, the mixture it was extracted from, has been approved since the 1960s U.S. Food and Drug Administration 2012. The 2026 British Society of Sexual Medicine document is titled a position statement for the potential use of enclomiphene Foster 2026 — which is the word a specialist society uses about a drug it cannot yet prescribe. Saffati 2024 reviews safety and efficacy across both compounds, and Hohl 2025 pools the randomized trials of clomiphene or enclomiphene in a meta-analysis. That is the top of the evidence pyramid for this compound: a meta-analysis of small trials, a specialist position statement, and no license.
The obstacles, specifically. (1) The largest trial named on this page randomized 48 men; the fertility result rests on 12. (2) Every trial ran for six months or less, and the men buying this run it for years. (3) There is no approved product, so the material in circulation is compounded or research-grade and its isomeric purity — the entire point of the drug — is the one property nobody verifies. A compounded ‘enclomiphene’ contaminated with zuclomiphene is chemically indistinguishable from clomiphene to anyone without a chiral assay. (4) No trial has used a hard endpoint: no pregnancies achieved, no fractures, no cardiovascular events.
Enclomiphene pharmacokinetics — how much of it actually gets in
Route: oral, once daily. And the most useful pharmacokinetic fact about this drug is a negative one. Wiehle 2013 performed pharmacokinetics in a subpopulation of its phase II and reported that “there was not a temporal association between the peak drug levels and the Cmax levels LH or TT”. The drug peaks; the hormones do not follow it. Whatever governs the size of the testosterone response, it is not the height of the enclomiphene curve on the same afternoon.
The second half of that finding is the one to plan around. In the same study, “the effects on LH and TT persisted for at least one week after stopping treatment” Wiehle 2013. Set that against the roughly ten-hour half-life this site's card carries: ten hours of drug, at least a week of effect. A receptor-occupancy drug acting on a pulsatile neuroendocrine axis does not have to be present for its consequence to be present, because what it changed was the set-point of a feedback loop, and loops have their own time constants. So the half-life is real and it is the wrong number to use for anything practical — timing a blood draw, judging a washout, or deciding whether a missed dose matters.
What clears it. Enclomiphene is a triphenylethylene, and the clomiphene label's disposition data covers both isomers: readily absorbed orally, excreted principally in the feces, with radiolabel still present in feces 6 weeks after a dose U.S. Food and Drug Administration 2012. Biliary excretion of a lipophilic molecule on that timescale implies hepatic conjugation and enterohepatic recycling. The critical difference from clomiphene is that the persistent species in that data is zuclomiphene, and a monoisomeric enclomiphene product does not contain it — so the tail belongs to the mixture, not to this molecule.
The arithmetic a reader can do. The doses that produced the published response were 6.25, 12.5 and 25 mg daily Wiehle 2013, and this site's card lists 12.5–25 mg. That is the rare case on this site where the community dose range sits inside a published trial's dose range rather than being extrapolated from a mouse. It is worth saying plainly, because it is unusual: the dose is not the weak part of this page. The weak part is that the trials lasted six months and enrolled dozens.
What would have to be true, and how you would know it was not
Five predictions with a marker, a direction and a window. The third is measured and cuts against the compound; the fifth is the one that separates this drug from a testosterone prescription.
1. LH & FSH should rise above the reference range, not into it. Wiehle 2013 reports enclomiphene increasing LH and FSH above normal while putting testosterone into normal. Draw LH & FSH at baseline and at 2 weeks. A high-normal or frankly high LH on this drug is the expected result and is evidence the hypothalamic block is working; an unchanged LH at two weeks means it is not, and no further waiting will change that.
2. Total Testosterone should reach the normal range within two weeks and hold. Both Wiehle 2013 and Kaminetsky 2013 reported testosterone rising within about two weeks and sustaining over months, landing near 525–604 ng/dL on the higher doses. Draw Total Testosterone trough — morning, before the dose — at 2 and 6 weeks.
3. The prediction that cuts against it: IGF-1 should fall. This is not extrapolation. Wiehle 2013 measured it: both transdermal testosterone and enclomiphene citrate decreased IGF-1 levels (p < 0.05), and the suppression was greater in the enclomiphene groups. Draw IGF-1 at baseline and at 6 weeks. Men take this drug during exactly the period they are trying to hold onto tissue, and the growth-hormone axis output falling further on enclomiphene than on testosterone gel is a measured cost that no vendor page mentions. If your IGF-1 does not fall, that contradicts the trial and is worth knowing too.
4. Estradiol should rise, and it should be left alone. Wiehle 2014 reports estradiol increasing alongside testosterone and LH. That is aromatase acting on more substrate. Order Estradiol, Sensitive (LC/MS-MS) on the same tube as the testosterone. Suppressing it with an aromatase inhibitor while blocking the hypothalamic estrogen receptor removes both the signal and its receptor, and there is no trial anywhere that has tested that combination in men.
5. Sperm concentration should be preserved or rise — and this is the only marker that distinguishes this drug from the alternative. Kaminetsky 2013 is explicit: 7 of 7 men at 3 months and 6 of 6 at 6 months on enclomiphene reached 75–334 × 106/mL, while every man on the gel stayed below 20 × 106/mL at 3 months. A semen analysis at baseline and 3 months is the single most informative test on this page, it is cheap, and almost nobody using this compound orders it.
What nobody has tested yet
Nobody has verified the isomeric purity of what people actually buy. The entire pharmacological case for enclomiphene is the absence of zuclomiphene Fontenot 2016, and with no approved product there is no batch-release specification for that absence. A chiral or geometric-isomer assay on twenty randomly purchased ‘enclomiphene’ capsules would settle in one afternoon whether the market is selling the drug the trials studied or a relabelled mixture. The method exists — a serum isomer assay was already used in men on clomiphene — and no such survey has been published.
Nobody knows whether the IGF-1 fall matters. Wiehle 2013 found it, quantified its direction and significance, and no follow-up has asked whether it translates into anything — body composition, bone turnover, recovery. A trial arm with IGF-1, lean mass by DEXA and a strength measure over six months would answer it, and the finding has sat unexamined since 2013.
Nobody has run enclomiphene against clomiphene head to head in men. This is the obvious study and it does not exist: the same men, randomized, with LH, FSH, testosterone, estradiol, semen analysis and the serum isomer assay, for six months. Hohl 2025 pools trials of ‘clomiphene or enclomiphene’ because there is no trial of clomiphene versus enclomiphene to pool. The entire premise of the more expensive drug rests on a mouse gavage study Fontenot 2016.
Nobody has taken it past six months in a trial. Every study named here ran for weeks to six months; men use it for years. Bone mineral density, hematocrit and lipids over two to five years of continuous hypothalamic estrogen-receptor blockade in men are unmeasured, and estrogen is the dominant regulator of male bone. That is the gap Foster 2026 is implicitly describing when it calls the use ‘potential’.
Enclomiphene — its own safety story, not its class's
Start with the honest structural fact: there is no label, so there are no label numbers. Enclomiphene has no FDA-approved product, which means no boxed warning, no adverse-reaction table with a denominator, no contraindication list and no post-marketing surveillance. That is a different situation from a drug that has been reviewed and found dangerous, and it is also different from a peptide nobody has ever tested — this molecule has randomized human trials Wiehle 2013 Wiehle 2014 Kaminetsky 2013 and no regulator has ever assembled them into a safety statement.
The nearest thing to a label is the parent mixture's, and it over-reads. Clomiphene's label reports visual symptoms in 1.5%, hot flushes in 10.4% and breast discomfort in 2.1% U.S. Food and Drug Administration 2012. Those rates come from women taking a two-isomer mixture for five days per cycle. Applying them to a man taking one isomer daily is an over-read in one direction (wrong sex, wrong schedule) and possibly an under-read in another (chronic dosing rather than five days). The visual one is still the one to respect: the label says prolonged visual disturbance has been reported and may be irreversible, and no monoisomeric preparation has been shown to be free of it.
The trial-level safety signal is reassuringly boring, and its size is the caveat. Wiehle 2013 reports that treatment with enclomiphene did not significantly affect TSH, ACTH, cortisol, lipids or bone markers over six weeks. That is a real, measured, negative result and it is worth more than a paragraph of reassurance. It is also six weeks in fewer than fifty men, which cannot detect anything uncommon.
The measured effect that is a cost rather than a risk. IGF-1 fell on enclomiphene, more than it fell on transdermal testosterone, p < 0.05 Wiehle 2013. Nobody has shown that this harms anyone. Nobody has shown that it does not. It is the only reproducibly measured downside in the compound's own trial record, and it deserves to be stated rather than buried.
The risk that is specific to buying it rather than to taking it. Because the drug is defined by what has been removed from it, a manufacturing failure here is invisible to the user: contaminated product still raises LH, still raises testosterone, still feels like it is working, and quietly restores the accumulating isomer that damaged Leydig cells, epididymis, seminal vesicles and kidneys in male mice Fontenot 2016. There is no symptom that reports isomeric purity. The only defense is a certificate of analysis that specifically quantifies zuclomiphene, and the reader should ask for that rather than for a generic purity figure.
Sources read for this page
- Wiehle R, Cunningham GR, Pitteloud N, Wike J, Hsu K, Fontenot GK, Rosner M, Dwyer A, Podolski J. Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics.. BJU Int 2013 · PMID 23875626
- Wiehle RD, Fontenot GK, Wike J, Hsu K, Nydell J, Lipshultz L. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone (ZA-203, NCT01270841).. Fertil Steril 2014 · PMID 25044085
- Kaminetsky J, Werner M, Fontenot G, Wiehle RD. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel.. J Sex Med 2013 · PMID 23530575
- Fontenot GK, Wiehle RD, Podolski JS. Differential effects of isomers of clomiphene citrate on reproductive tissues in male mice.. BJU Int 2016 · PMID 26220499
- Foster J, Choo L, Patel A, Kirby M, Hackett G. British Society of Sexual Medicine: Position Statement for the Potential Use of Enclomiphene in the Treatment of Male Hypogonadism.. World J Mens Health 2026 · PMID 41714894
- Saffati G, Kassab J, Orozco Rendon D, Hinojosa-Gonzalez DE, Kronstedt S, Lipshultz LI, Khera M. Safety and efficacy of enclomiphene and clomiphene for hypogonadal men.. Transl Androl Urol 2024 · PMID 39434750
- Hohl A, Chavez MP, Pasqualotto E, Ferreira ROM, Sande-Lee SV, Ronsoni MF. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials.. Arch Endocrinol Metab 2025 · PMID 41066380
- U.S. Food and Drug Administration. CLOMID (clomiphene citrate) tablets USP - full prescribing information (NDA 016131).. FDA approved labeling, revision 2012
Enclomiphene — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Two different mechanisms with one shared consequence: less estrogen signaling. Aromatase inhibitors (anastrozole, exemestane) stop testosterone converting to estradiol; SERMs (tamoxifen, raloxifene, clomiphene, enclomiphene) block or activate the receptor depending on the tissue.
- The predicted harm is the same either way and it is not the one people expect. Estrogen is not a side effect to be eliminated — it is required for bone density, joint comfort, lipid handling, libido and mood in men as well as women. Crushing it produces aching joints, flat libido, low mood and, over years, measurable bone loss.
- Clomiphene specifically is a mixture of two isomers and the longer-lived one (zuclomiphene) accumulates; the visual disturbances reported on it are attributed to that accumulation. Enclomiphene is the isolated isomer, which is the entire argument for it.
What has actually been reported
- Well documented in oncology use: hot flushes, joint pain and reduced bone mineral density on AIs; venous thromboembolism and endometrial changes on tamoxifen.
- Visual disturbance on clomiphene is uncommon but real and is a reason to stop rather than push through.
How to reduce the risk
Same mechanism as the prediction.
- The dose almost everyone gets wrong is the AI dose. These are used in oncology to drive estradiol as close to zero as possible; that is a cancer-treatment goal and it is the wrong target for anyone else. Most people feeling terrible on a protocol are over-suppressing estradiol.
- Measure before adjusting, and measure with the sensitive (LC-MS/MS) estradiol assay — the standard immunoassay is unreliable in men and produces numbers people then medicate.
- If an AI is genuinely needed, the lowest effective dose intermittently beats a fixed daily one. Bone density is worth tracking on anything run for more than a year.
What it does to your bloodwork
A fact about the assay.
- Sensitive estradiol, total and free testosterone, LH and FSH, a lipid panel, and — for long-term use — a DEXA for bone density.
Don't run this if
- You are only using one because of a number rather than a symptom. An estradiol reading with no symptoms attached is not a reason to medicate.
The honest unknown
- Long-term outcomes of AI use in otherwise healthy men, at the doses used outside oncology, have not been studied. The bone and lipid consequences are extrapolated from populations taking them for a different reason.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Enclomiphene — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Enclomiphene moves on your bloodwork
Expected direction, not a measured one.
- Complete Blood Count (CBC) with Differential — ↑ expected to rise
Hematocrit and hemoglobin rise — androgens stimulate erythropoiesis. This is the most reliably predictable movement of any compound in the Vault.
What to do: This is the number that decides whether you keep going. Baseline and every 3 months. Dehydration on the draw day inflates it, so hydrate normally or you will chase a false reading. - Total Testosterone — ↑ expected to rise
Expected. Trough vs peak matters enormously — the same protocol reads completely differently depending on when you drew.
What to do: Draw at the same point in the cycle every time or the trend is noise. - LH & FSH — ↓ expected to fall
Suppressed by negative feedback. This is the mechanism, not a side effect — and it is why exogenous androgen shuts down your own production.
What to do: Relevant if fertility matters to you. Worth knowing before, not after. - Estradiol, Sensitive (LC/MS-MS) — ↑ expected to rise
Aromatization converts a fraction to estradiol, and it rises with the androgen. Use the sensitive (LC-MS/MS) assay — the standard immunoassay is unreliable in men and produces numbers people then medicate.
What to do: If you are reading estradiol in a man, the assay choice matters more than the result. - SHBG (Sex Hormone-Binding Globulin) — ↓ expected to fall
Falls with androgen exposure, which raises the free fraction — so free testosterone can climb faster than total.
What to do: Read total and SHBG together; total alone understates what changed. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to worsen
HDL falls, sometimes markedly. Oral 17-alpha-alkylated compounds do this far more aggressively than injectable esters.
What to do: Baseline and 12 weeks. ApoB is the better long-term read than LDL-C. - PSA (Total + Free + % Free) — ↑ expected to rise
Androgens can raise PSA modestly. It does not create prostate cancer that wasn't there, but it can unmask it.
What to do: Baseline before starting matters — without it, a later number has nothing to be compared against.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Enclomiphene in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Enclomiphene
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| LH & FSH | Enclomiphene works by raising these |
| Total Testosterone | The outcome |
| Estradiol, Sensitive (LC/MS-MS) | Blocking estrogen receptors changes this reading's meaning |
| SHBG (Sex Hormone-Binding Globulin) | Rises on SERMs, which blunts the free testosterone gain |
The Post-Cycle / Recovery & Fertility panel covers these in one order — 9 markers, $184.50 with the discount applied.
Check results you already have → · All 103 markers A–Z
Enclomiphene — frequently asked questions
What is Enclomiphene?
Enclomiphene (Enclomiphene citrate) is a hormonal & sexual research compound. Estrogen-receptor antagonist at the hypothalamus — removes estrogen's brake so LH/FSH rise and testicular testosterone increases.
Is the full Enclomiphene protocol on this page?
The reported research dose is on this page, along with how Enclomiphene works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Enclomiphene?
Enclomiphene has an approximate half-life of ~10 hrs, which is part of what determines how often it's dosed.
What's the evidence behind Enclomiphene?
Current evidence level: Human trials. Enclomiphene is offered for research purposes only and is not an approved medicine.
Enclomiphene inside a finished plan
One arm of 3 Protocol Blueprints, free to read in full.
What Enclomiphene is used for
Enclomiphene appears under 3 goals in the goal router.
Related Hormonal & Sexual compounds
Where this goes next
Enclomiphene is the androgen-signaling arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.